Bcl10 and methylation of fatty acids: A future therapeutic target for Type 2 diabetes?

Clinical Lipidology

Volumn 7, Issue 5, 2012, Pages 493-495

  Jornayvaz, François R ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

fatty acids; inflammation; insulin resistance; NAFLD; obesity; Type 2 diabetes

Indexed keywords

CHYLOMICRON; DIACYLGLYCEROL; FAT DROPLET; FATTY ACID; INSULIN RECEPTOR KINASE; INTERLEUKIN 6; LIPID; PROTEIN BCL 10; PROTEIN KINASE C EPSILON; SALSALATE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

B LYMPHOCYTE; CALORIC INTAKE; DIABETOGENESIS; DRUG TARGETING; ENZYME ACTIVATION; FAT INTAKE; FATTY ACID METABOLISM; FATTY ACID METHYLATION; FATTY ACID OXIDATION; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; LYMPHOCYTE PROLIFERATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; T LYMPHOCYTE; WEIGHT REDUCTION;

EID: 84869382804     PISSN: 17584299     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.12.56     Document Type: Review

References (21)

1. Jornayvaz FR, Shulman GI. Diacylglycerol activation of protein kinase Cepsilon and hepatic insulin resistance. Cell Metab. 15(5), 574-584 (2012).
2. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatology 51(2), 679-689 (2010).
3. Samuel VT, Liu ZX, Qu X et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem. 279(31), 32345-32353 (2004). (Pubitemid 39014687)
4. Jornayvaz FR, Birkenfeld AL, Jurczak MJ et al. Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2. Proc. Natl Acad. Sci. USA 108(14), 5748-5752 (2011).
5. Jornayvaz FR, Jurczak MJ, Lee HY et al. A high-fat, ketogenic diet causes hepatic insulin resistance in mice, despite increasing energy expenditure and preventing weight gain. Am. J. Physiol. Endocrinol. Metab. 299(5), e808-e815 (2010).
6. Jornayvaz FR, Lee HY, Jurczak MJ et al. Thyroid hormone receptor-alpha gene knockout mice are protected from dietinduced hepatic insulin resistance. Endocrinology 153(2), 583-591 (2012).
7. Lee HY, Birkenfeld AL, Jornayvaz FR et al. Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology 54(5), 1650-1660 (2011).
8. Kumashiro N, Erion DM, Zhang D et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc. Natl Acad. Sci. USA 108(39), 16381-16385 (2011).
9. Schmid AI, Szendroedi J, Chmelik M, Krssak M, Moser E, Roden M. Liver ATP synthesis is lower and relates to insulin sensitivity in patients with Type 2 diabetes. Diabetes Care 34(2), 448-453 (2011).
10. Sunny NE, Parks EJ, Browning JD, Burgess SC. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab. 14(6), 804-810 (2011).
11. Petersen KF, Dufour S, Savage DB et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc. Natl Acad. Sci. USA 104(31), 12587-12594 (2007). (Pubitemid 47255198)
12. Rabol R, Petersen KF, Dufour S, Flannery C, Shulman GI. Reversal of muscle insulin resistance with exercise reduces postprandial hepatic de novo lipogenesis in insulin resistant individuals. Proc. Natl Acad. Sci. USA 108(33), 13705-13709 (2011).
13. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J. Clin. Invest. 116(7), 1793-1801 (2006). (Pubitemid 44033299)
14. Baker RG, Hayden MS, Ghosh S. NF-kB, inflammation, and metabolic disease. Cell Metab. 13(1), 11-22 (2011).
15. Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J. Biol. Chem. 276(20), 16683-16689 (2001).
16. Ruland J, Duncan GS, Elia A et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure. Cell 104(1), 33-42 (2001). (Pubitemid 32144970)
17. Wegener E, Krappmann D. CARD-Bcl10-Malt1 signalosomes: Missing link to NF-kappaB. Sci. STKE 384, pe21 (2007).
18. van Beek M, Oravecz-Wilson KI, Delekta PC et al. Bcl10 links saturated fat overnutrition with hepatocellular NF-kappaB activation and insulin resistance. Cell Rep. 1(5), 444-452 (2012).
19. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with Type 2 diabetes. Diabetes 54(3), 603-608 (2005). (Pubitemid 40322060)
20. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45(7), 881-885 (1996). (Pubitemid 26225502)
21. Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE. The effects of salsalate on glycemic control in patients with Type 2 diabetes: A randomized trial. Ann. Intern. Med. 152(6), 346-357 (2010).